Small molecule trail gene induction by normal and tumor cells as an anticancer therapy

Abstract

Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

The invention claimed is: 
     
       1. A method of treatment of a subject having brain cancer, comprising:
 administering to the subject a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Formula (I): 
 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 
     
     
       2. The method of treatment of  claim 1 , wherein the brain cancer is glioblastoma multiforme. 
     
     
       3. The method of  claim 1 , further comprising administering a second therapeutic to the subject, wherein the second therapeutic agent comprises an anti-cancer agent. 
     
     
       4. The method of  claim 1 , further comprising administering a second therapeutic to the subject, wherein the second therapeutic agent comprises an anti-angiogenic agent. 
     
     
       5. The method of  claim 3 , wherein the anti-cancer agent is a mitotic inhibitor. 
     
     
       6. The method of  claim 3 , wherein the anti-cancer agent is selected from the group consisting of paclitaxel, docetaxel and a combination thereof. 
     
     
       7. The method of  claim 4 , wherein the anti-angiogenic agent is bevacizumab. 
     
     
       8. The method of  claim 1 , wherein the pharmaceutical composition is administered orally. 
     
     
       9. The method of  claim 1 , wherein the pharmaceutical composition is administered via a route of administration selected from the group consisting of rectal, nasal, pulmonary, epidural, ocular, otic, intraarterial, intracardiac, intracerebroventricular, intradermal, intravenous, intramuscular, intraperitoneal, intraosseous, intrathecal, intravesical, subcutaneous, topical, transdermal, transmucosal, sublingual, buccal, vaginal, and inhalational routes of administration. 
     
     
       10. The method of  claim 1 , further including assessing effectiveness of the treatment. 
     
     
       11. The method of  claim 10 , wherein assessment of the effectiveness of the treatment comprises assaying TNF-related apoptosis-inducing ligand in a biological sample obtained from the subject. 
     
     
       12. The method of  claim 11 , wherein the biological sample is selected from the group consisting of blood, serum, plasma and cerebrospinal fluid.